tnfs are major mediators of inflammation and inflammationrelated diseases hence the united states food and drug administration fda has approved the use of blockers of the cytokine tnfα for the treatment of osteoarthritis inflammatory bowel disease psoriasis and ankylosisthese drugs include the chimeric tnf antibody infliximab humanized tnfα antibody humira and soluble tnf receptorii enbrel and are associated with a total cumulative market value of more than 20 billion a yearas well as being expensive 15 00020 000 per person per year these drugs have to be injected and have enough adverse effects to be given a black label warning by the fdain the current report we describe an alternative curcumin diferuloylmethane a component of turmeric curcuma longa that is very inexpensive orally bioavailable and highly safe in humans yet can block tnfα action and production in in vitro models in animal models and in humansin addition we provide evidence for curcumins activities against all of the diseases for which tnf blockers are currently being usedmechanisms by which curcumin inhibits the production and the cell signalling pathways activated by this cytokine are also discussedwith healthcare costs and safety being major issues today this golden spice may help provide the solutionlinked articles this article is part of a themed section on emerging therapeutic aspects in oncologyto view the other articles in this section visit httpdxdoiorg101111bph2013169issue8